Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pseudolaric acid B is a diterpene acid isolated from the bark of Pseudolarix kaempferi, known for its antifungal, antifertility, anti-inflammatory, immunomodulatory, antiangiogenic, and antitumor properties[2][4][6][8][9]. Its main mechanism of action is as a microtubule-destabilizing agent, causing mitotic arrest and apoptosis in tumor cells by inhibiting tubulin polymerization[7][9]. Pseudolaric acid B also circumvents multidrug resistance mediated by P-glycoprotein and affects multiple signaling pathways involved in inflammation and apoptosis, including NF-κB, p38 MAPK, COX-2, PKC-α, and others[1][5][7]. It induces autophagy, modulates immune responses, and demonstrates efficacy in preclinical models of cancer and inflammatory diseases such as atopic dermatitis[5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pseudolaric acid B.